menu
    • menu

    Company profile for Somerset Pharmaceuticals Inc

    NEW Drugs in Dev: 1
    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    Contact Supplier

    LEBSA- Your strategic API source for niche molecules.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Somerset Pharmaceuticals, Inc. operates as a researcher and developer of Parkinson's disease pharmaceuticals. The company markets Eldepryl in capsule form for the treatment of patients with late-stage Parkinson's Disease. Somerset Pharmaceuticals, Inc. was founded in 1986 and is based in Tampa, Florida. Somerset Pharmaceuticals, Inc. operates as a subsidiary of Mylan, Inc.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Somerset Pharmaceuticals IncUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    5215 W. Laurel St. Tampa, FL 33607
    Telephone
    Telephone
    +1-813-288-0040
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    http://www.somersetpharm.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Somerset’ s Generics Eltrombopag Olamine Receives Approval in US
    Somerset’ s Generics Eltrombopag Olamine Receives Approval in US

    14 Jan 2026

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=219638

    FDA
    14 Jan 2026
    Share Share
    Somerset’s Generics Rilpivirine Receives Tentative Approval in US
    Somerset’s Generics Rilpivirine Receives Tentative Approval in US

    20 Aug 2025

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218798

    FDA
    20 Aug 2025
    Share Share
    Enforcement Report - Week of April 30, 2025
    Enforcement Report - Week of April 30, 2025

    30 Apr 2025

    // FDA

    https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-april-30-2025-42831.pdf

    FDA
    30 Apr 2025
    Share Share
    Enforcement Report - Week of April 16, 2025
    Enforcement Report - Week of April 16, 2025

    16 Apr 2025

    // FDA

    https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-april-16-2025-39741.pdf

    FDA
    16 Apr 2025
    Share Share
    Somerset’ Receives First Generic Approval for Phenylephrine in US
    Somerset’ Receives First Generic Approval for Phenylephrine in US

    14 Feb 2025

    // FDA

    http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=215617

    FDA
    14 Feb 2025
    Share Share
    Lupin's Somerset Facility Clears USFDA Inspection With Zero 483
    Lupin's Somerset Facility Clears USFDA Inspection With Zero 483

    04 Feb 2025

    // BUSINESS STD

    https://www.business-standard.com/markets/capital-market-news/lupin-s-somerset-based-facility-completes-us-fda-inspection-with-zero-form-483-observations-125020300585_1.html

    BUSINESS STD
    04 Feb 2025
    Share Share

    Inspections and registrations

    Upload your audits for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search